2-170716535-G-C
Position:
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BP4_StrongBS2
The ENST00000375281.4(SP5):āc.328G>Cā(p.Glu110Gln) variant causes a missense change. The variant allele was found at a frequency of 0.000218 in 1,611,226 control chromosomes in the GnomAD database, including 2 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Genomes: š 0.00018 ( 0 hom., cov: 33)
Exomes š: 0.00022 ( 2 hom. )
Consequence
SP5
ENST00000375281.4 missense
ENST00000375281.4 missense
Scores
2
5
12
Clinical Significance
Conservation
PhyloP100: 6.55
Genes affected
SP5 (HGNC:14529): (Sp5 transcription factor) Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to act upstream of or within bone morphogenesis; cellular response to organic cyclic compound; and post-anal tail morphogenesis. Predicted to be located in nucleus. Predicted to be part of chromatin. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -8 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.020376652).
BS2
High AC in GnomAd4 at 28 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SP5 | NM_001003845.3 | c.328G>C | p.Glu110Gln | missense_variant | 2/2 | ENST00000375281.4 | NP_001003845.1 | |
ERICH2-DT | NR_110185.1 | n.376+6969C>G | intron_variant, non_coding_transcript_variant | |||||
SP5 | XM_005246542.5 | c.460G>C | p.Glu154Gln | missense_variant | 2/2 | XP_005246599.1 | ||
SP5 | XM_047444264.1 | c.100G>C | p.Glu34Gln | missense_variant | 2/2 | XP_047300220.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SP5 | ENST00000375281.4 | c.328G>C | p.Glu110Gln | missense_variant | 2/2 | 1 | NM_001003845.3 | ENSP00000364430 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000191 AC: 29AN: 152078Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
29
AN:
152078
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000353 AC: 82AN: 232392Hom.: 0 AF XY: 0.000366 AC XY: 47AN XY: 128568
GnomAD3 exomes
AF:
AC:
82
AN:
232392
Hom.:
AF XY:
AC XY:
47
AN XY:
128568
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000222 AC: 324AN: 1459036Hom.: 2 Cov.: 38 AF XY: 0.000255 AC XY: 185AN XY: 725832
GnomAD4 exome
AF:
AC:
324
AN:
1459036
Hom.:
Cov.:
38
AF XY:
AC XY:
185
AN XY:
725832
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000184 AC: 28AN: 152190Hom.: 0 Cov.: 33 AF XY: 0.000175 AC XY: 13AN XY: 74416
GnomAD4 genome
AF:
AC:
28
AN:
152190
Hom.:
Cov.:
33
AF XY:
AC XY:
13
AN XY:
74416
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
37
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 28, 2022 | The c.328G>C (p.E110Q) alteration is located in exon 2 (coding exon 2) of the SP5 gene. This alteration results from a G to C substitution at nucleotide position 328, causing the glutamic acid (E) at amino acid position 110 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Benign
T
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D
M_CAP
Uncertain
D
MetaRNN
Benign
T
MetaSVM
Benign
T
MutationAssessor
Uncertain
M
MutationTaster
Benign
D
PrimateAI
Pathogenic
D
PROVEAN
Benign
N
REVEL
Benign
Sift
Uncertain
D
Sift4G
Benign
T
Polyphen
P
Vest4
MVP
ClinPred
T
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at